A controversial figure in abortion debates, the nominee would play a key role in the FDA’s review of mifepristone, the most widely used medication for abortion in the U.S. Their stance as a vocal opponent of abortion could shape the outcome of the assessment, raising questions about potential policy shifts. The decision comes amid ongoing legal and political battles over reproductive rights. Critics and supporters alike are closely watching how this appointment may influence access to the drug.
Overton is an outspoken abortion critic and would oversee an ongoing FDA review of mifepristone, the nation's leading abortion pill.
